Abstract:Importance: Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021, the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100 000 to 21.9 per 100 000 people. Observations: The most common causes of cirrhosis in the US, which can overlap, include alcohol use disorder (approximately 45% of all cases of cirrhosis), nonalcoholic fatty liver disease (26%), and hepatitis C (41%). Patients with cirrhosis experience symptoms including muscle cramps (approximately 64% prevalence), pruritus (39%), poor-quality sleep (63%), and sexual dysfunction (53%). Cirrhosis can be diagnosed by liver biopsy but may also be diagnosed noninvasively. Elastography, a noninvasive assessment of liver stiffness measured in kilopascals, can typically confirm cirrhosis at levels of 15 kPa or greater. Approximately 40% of people with cirrhosis are diagnosed when they present with complications such as hepatic encephalopathy or ascites. The median survival time following onset of hepatic encephalopathy and ascites is 0.92 and 1.1 years, respectively. Among people with ascites, the annual incidence of spontaneous bacterial peritonitis is 11% and of hepatorenal syndrome is 8%; the latter is associated with a median survival of less than 2 weeks. Approximately 1% to 4% of patients with cirrhosis develop hepatocellular carcinoma each year, which is associated with a 5-year survival of approximately 20%. In a 3-year randomized clinical trial of 201 patients with portal hypertension, nonselective β-blockers (carvedilol or propranolol) reduced the risk of decompensation or death compared with placebo (16% vs 27%). Compared with sequential initiation, combination aldosterone antagonist and loop diuretics were more likely to resolve ascites (76% vs 56%) with lower rates of hyperkalemia (4% vs 18%). In meta-analyses of randomized trials, lactulose was associated with reduced mortality relative to placebo (8.5% vs 14%) in randomized trials involving 705 patients and reduced risk of recurrent overt hepatic encephalopathy (25.5% vs 46.8%) in randomized trials involving 1415 patients. In a randomized clinical trial of 300 patients, terlipressin improved the rate of reversal of hepatorenal syndrome from 39% to 18%. Trials addressing symptoms of cirrhosis have demonstrated efficacy for hydroxyzine in improving sleep dysfunction, pickle brine and taurine for reducing muscle cramps, and tadalafil for improving sexual dysfunction in men. Conclusions and relevance: Approximately 2.2 million US adults have cirrhosis. Many symptoms, such as muscle cramps, poor-quality sleep, pruritus, and sexual dysfunction, are common and treatable. First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome.

Prescription rates of common medications in patients with decompensated cirrhosis in Germany

Drug treatments to prevent first decompensation in cirrhosis

Current and future pharmacological therapies for managing cirrhosis and its complications

Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes

Non-selective beta-blockers lower the risk of first decompensation in patients with cirrhosis and enduring clinically significant portal hypertension after etiological treatment

The Use of Proton Pump Inhibitors in Patients with Liver Cirrhosis: Real Life Experience

Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review

Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018)

[CME: Outpatient Management of Patients with Liver Cirrhosis]

The portal hypertension syndrome: etiology, classification, relevance, and animal models

β-BLOCKERS LOWER FIRST DECOMPENSATION IN PATIENTS WITH CIRRHOSIS AND ENDURING PORTAL HYPERTENSION AFTER ETIOLOGICAL TREATMENT

Antibiotic prophylaxis in cirrhosis: Good and bad

Interobserver Agreement for Classifying Infections in Patients with Decompensated Cirrhosis Based on Centers for Disease Control and Prevention Criteria

Factors associated with medication adherence in patients living with cirrhosis

Beta-blockers and Cirrhosis: Striking the Right Balance

Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy

Diagnosis and Management of Cirrhosis and Its Complications: A Review

Emergency Department Utilization and Outcomes among Adults with Cirrhosis from 2008 to 2022 in the United States

Discharge Outcomes of Hospitalized Patients with New Onset Decompensated Cirrhosis

A cross-sectional survey on the cognition of common sense treatments on liver cirrhosis complications in decompensated patients with hepatitis B cirrhosis

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis